UnitedHealth Group Incorporated operates as a diversified health care company in the United States. The company operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health care coverage, and health and well-being services to individuals age 50 and older addressing their needs; Medicaid plans, children's health insurance and health care programs; and health and dental benefits, and hospital and clinical services, as well as health care benefits products and services to state programs caring for the economically disadvantaged, medically underserved, and those without the benefit of employer-funded health care coverage. The Optum Health segment provides care delivery, care management, wellness and consumer engagement, and health financial services patients, consumers, care delivery systems, providers, employers, payers, and public-sector entities. The Optum Insight segment offers software and information products, advisory consulting arrangements, and managed services outsourcing contracts to hospital systems, physicians, health plans, governments, life sciences companies, and other organizations. The Optum Rx segment provides pharmacy care services and programs, including retail network contracting, home delivery, specialty and community health pharmacy services, infusion, and purchasing and clinical capabilities, as well as develops programs in the areas of step therapy, formulary management, drug adherence, and disease/drug therapy management. UnitedHealth Group Incorporated was founded in 1974 and is based in Minnetonka, Minnesota.

UnitedHealth Group Incorporated

Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in UnitedHealth Group Inc (Symbol: UNH), where a total of 252,370 contracts have traded so far, representing approximately 25.2 million underlying shares. That amounts to about 322.7% of UNH's average daily trading volume over the past month of 7.8 million shares. Particularly high volume was seen for the $400 strike call option expiring October 31, 2025, with 13,660 contracts trading so far today, representing approximately 1.4 million underlying shares of UNH. Below is a chart showing UNH's trailing twelve month trading history, with the $400 strike highlighted in orange:
State Street Corp. (Symbol: STT) options are showing a volume of 40,552 contracts thus far today. That number of contracts represents approximately 4.1 million underlying shares, working out to a sizeable 189.1% of STT's average daily trading volume over the past month, of 2.1 million shares. Particularly high volume was seen for the $130 strike call option expiring January 16, 2026, with 20,145 contracts trading so far today, representing approximately 2.0 million underlying shares of STT. Below is a chart showing STT's trailing twelve month trading history, with the $130 strike highlighted in orange:
And Qualcomm Inc (Symbol: QCOM) saw options trading volume of 176,589 contracts, representing approximately 17.7 million underlying shares or approximately 157.9% of QCOM's average daily trading volume over the past month, of 11.2 million shares. Especially high volume was seen for the $200 strike call option expiring October 31, 2025, with 10,070 contracts trading so far today, representing approximately 1.0 million underlying shares of QCOM. Below is a chart showing QCOM's trailing twelve month trading history, with the $200 strike highlighted in orange:
For the various different available expirations for UNH options, STT options, or QCOM options, visit StockOptionsChannel.com.
Also see:
Top Ten Hedge Funds Holding ENDO
Top Ten Hedge Funds Holding IFMK
Institutional Holders of TACA
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Noteworthy Tuesday Option Activity: UNH, STT, QCOM

UnitedHealth Group Incorporated UNH reported third-quarter 2025 adjusted earnings per share (EPS) of $2.92, which beat the Zacks Consensus Estimate of $2.75. However, the bottom line declined 59.2% year over year.
Revenues rose 12% year over year to $113.2 billion. The top line missed the consensus mark by 0.2%.
The quarterly earnings were aided by growth in domestic commercial membership and strength witnessed in Optum Rx. However, elevated medical costs partially offset the positives.
UnitedHealth Group Incorporated Price, Consensus and EPS Surprise
Business Performance of UNH
UnitedHealth’s third-quarter premium of $89 billion increased from $77.4 billion a year ago but missed the consensus mark by 0.2%.
UNH’s medical care ratio (MCR) was 89.9% in the third quarter, which deteriorated 470 bps from the year-ago period. The metric was lower than the Zacks Consensus Estimate of 90.9% and our estimate of 91.1%. MCR witnessed an increase due to the previously noted reductions in Medicare funding and medical cost trend, which exceeded the pricing trend. Medical costs of $80 billion rose from $66 billion a year ago.
Third-quarter total operating costs of $108.8 billion escalated 18.2% year over year due to higher medical costs, operating costs and the cost of products sold. The figure came higher than our model estimate of $108.7 billion. The third-quarter 2025 operating cost ratio deteriorated to 13.5% from 13.2% in 2024 due to investments.
UnitedHealth’s operating earnings declined 50% year over year to $4.3 billion in the third quarter. The net margin deteriorated 390 bps to 2.1% from the year-ago period.
Performance of UNH’s Business Platforms
Revenues of the health benefits business of UnitedHealth, UnitedHealthcare, advanced 16% year over year to $87.1 billion in the third quarter due to an increase in domestic commercial membership growth. The metric beat the Zacks Consensus Estimate of $87 billion.
Earnings from operations amounted to $1.8 billion, down from $4.2 billion a year ago. The operating margin decreased 350 bps year over year to 2.1%.
Revenues in the Optum business line were $69.2 billion, which rose 8% year over year due to strong contributions from Optum Rx. The figure surpassed the consensus mark of $67.7 billion.
Optum’s earnings from operations declined to $2.5 billion from $4.5 billion a year ago. The operating margin of 3.6% decreased 340 bps year over year.
UnitedHealth’s Medical Membership
The UnitedHealthcare business catered to 50.1 million people as of Sept. 30, 2025, which grew 1.6% year over year due to its self-funded commercial benefits. However, the figure missed the Zacks Consensus Estimate and our estimate of 50.3 million.
UNH’s Financial Position (As of Sept. 30, 2025)
UnitedHealth exited the third quarter with cash and short-term investments of $30.6 billion, which rose from the 2024-end level of $29.1 billion.
Total assets of $315.3 billion increased from the $298.3 billion figure at 2024-end.
Long-term debt, less of current maturities, amounted to $72.4 billion, up 0.1% from the figure as of Dec. 31, 2024. Short-term borrowings and the current portion of long-term debt were $7.7 billion.
Total equity of $101.6 billion advanced from the 2024-end level of $98.3 billion.
UnitedHealth generated operating cash flows of $18.6 billion in the first nine months of 2025, which declined from the prior-year figure of $21.8 billion.
UNH’s 2025 Outlook
Management now projects adjusted net EPS to be at least $16.25 for 2025, up from the previous guided figure of $16 compared with the 2024 figure of $27.66. Net earnings are now expected to be at least $14.9 billion, up from the 2024 level of $14.4 billion.
Revenues were earlier projected between $445.5 billion and $448 billion in 2025, up from $400.3 billion in 2024. Operating cash flows were estimated to be $16 billion, down from $24.2 billion in 2024.
UNH’s Zacks Rank
UNH currently carries a Zacks Rank #3 (Hold).
Stocks to Report Earnings
Here are three companies from the Medical space that are likely to report their respective quarterly earnings soon.
ANI Pharmaceuticals, Inc. ANIP carries a Zacks Rank of 2 (Buy) at present. The Zacks Consensus Estimate for ANIP’s bottom line for the to-be-reported quarter is pegged at $1.74 per share, indicating 29.9% year-over-year growth. ANI Pharmaceuticals’ earnings beat estimates in each of the past four quarters, with an average surprise of 22.7%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Encompass Health Corporation EHC has a Zacks Rank of 2 at present. The Zacks Consensus Estimate for EHC’s bottom line for the to-be-reported quarter is pegged at $1.19 per share, indicating 15.5% year-over-year growth. Encompass Health’s earnings beat estimates in each of the past four quarters, with an average surprise of 14%.
The Cigna Group CI currently has a Zacks Rank of 3. The Zacks Consensus Estimate for CI’s bottom line for the to-be-reported quarter of $7.70 per share indicates 2.5% year-over-year growth. It remained stable over the past week. Cigna Group’s earnings beat estimates in three of the last four quarters and missed once.
Quantum Computing Stocks Set To Soar
Artificial intelligence has already reshaped the investment landscape, and its convergence with quantum computing could lead to the most significant wealth-building opportunities of our time.
Today, you have a chance to position your portfolio at the forefront of this technological revolution. In our urgent special report, Beyond AI: The Quantum Leap in Computing Power, you'll discover the little-known stocks we believe will win the quantum computing race and deliver massive gains to early investors.
Access the Report Free Now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

UnitedHealth Q3 Earnings Beat on Rising Commercial Membership

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR S&P 500 ETF Trust (Symbol: SPY) where we have detected an approximate $2.5 billion dollar outflow -- that's a 0.4% decrease week over week (from 1,013,632,116 to 1,009,982,116). Among the largest underlying components of SPY, in trading today UnitedHealth Group Inc (Symbol: UNH) is up about 0.3%, Coca-Cola Co (Symbol: KO) is up about 0.8%, and Wells Fargo & Co (Symbol: WFC) is up by about 0.2%. For a complete list of holdings, visit the SPY Holdings page » The chart below shows the one year price performance of SPY, versus its 200 day moving average:
Looking at the chart above, SPY's low point in its 52 week range is $481.80 per share, with $687.225 as the 52 week high point — that compares with a last trade of $685.91. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average ».
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Also see:
VC Next Dividend Date
CHWA Historical Stock Prices
Institutional Holders of CLNS
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Noteworthy ETF Outflows: SPY, UNH, KO, WFC

The NASDAQ 100 Pre-Market Indicator is up 53.64 to 25,875.19. The total Pre-Market volume is currently 181,298,497 shares traded.
The following are the most active stocks for the pre-market session:
SoFi Technologies, Inc. (SOFI) is +1.2302 at $31.23, with 12,886,791 shares traded. Smarter Analyst Reports: SoFi Concludes Acquisition of Technisys
Direxion Daily TSLA Bull 2X Shares (TSLL) is +0.39 at $21.64, with 9,647,229 shares traded. This represents a 244.04% increase from its 52 Week Low.
PayPal Holdings, Inc. (PYPL) is +10.3999 at $80.65, with 7,959,798 shares traded. Smarter Analyst Reports: Post 65% Decline, What’s Ahead for PayPal Stock?
ProShares UltraPro Short QQQ (SQQQ) is -0.08 at $13.14, with 4,225,927 shares traded., following a 52-week high recorded in prior regular session.
NVIDIA Corporation (NVDA) is +1.51 at $193.00, with 3,640,594 shares traded. As reported by Zacks, the current mean recommendation for NVDA is in the "buy range".
Bitfarms Ltd. (BITF) is -0.11 at $4.43, with 2,210,212 shares traded. As reported by Zacks, the current mean recommendation for BITF is in the "buy range".
United Parcel Service, Inc. (UPS) is +11.0228 at $100.24, with 2,130,651 shares traded. UPS's current last sale is 100.24% of the target price of $100.
UnitedHealth Group Incorporated (UNH) is +17.395 at $383.38, with 1,426,129 shares traded. Over the last four weeks they have had 3 up revisions for the earnings forecast, for the fiscal quarter ending Dec 2025. The consensus EPS forecast is $2.07. As reported by Zacks, the current mean recommendation for UNH is in the "buy range".
AT&T Inc. (T) is -0.0399 at $25.49, with 1,184,165 shares traded. As reported by Zacks, the current mean recommendation for T is in the "buy range".
Cameco Corporation (CCJ) is +13.68 at $100.30, with 1,084,287 shares traded. As reported by Zacks, the current mean recommendation for CCJ is in the "buy range".
Norwegian Cruise Line Holdings Ltd. (NCLH) is -0.81 at $22.70, with 908,061 shares traded.NCLH is scheduled to provide an earnings report on 11/4/2025, for the fiscal quarter ending Sep2025. The consensus earnings per share forecast is 1.11 per share, which represents a 97 percent increase over the EPS one Year Ago
NuScale Power Corporation (SMR) is +1.0495 at $39.76, with 844,905 shares traded. SMR's current last sale is 104.63% of the target price of $38.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Pre-Market Most Active for Oct 28, 2025 : SOFI, TSLL, PYPL, SQQQ, NVDA, BITF, UPS, UNH, T, CCJ, NCLH, SMR

UnitedHealth Group (UNH) came out with quarterly earnings of $2.92 per share, beating the Zacks Consensus Estimate of $2.75 per share. This compares to earnings of $7.15 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of +6.18%. A quarter ago, it was expected that this largest U.S. health insurer would post earnings of $4.84 per share when it actually produced earnings of $4.08, delivering a surprise of -15.7%.
Over the last four quarters, the company has surpassed consensus EPS estimates two times.
UnitedHealth, which belongs to the Zacks Medical - HMOs industry, posted revenues of $113.16 billion for the quarter ended September 2025, missing the Zacks Consensus Estimate by 0.17%. This compares to year-ago revenues of $100.82 billion. The company has topped consensus revenue estimates just once over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
UnitedHealth shares have lost about 27.7% since the beginning of the year versus the S&P 500's gain of 16.9%.
What's Next for UnitedHealth?
While UnitedHealth has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for UnitedHealth was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $2.07 on $113.87 billion in revenues for the coming quarter and $16.15 on $448.36 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - HMOs is currently in the bottom 26% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Humana (HUM), another stock in the same industry, has yet to report results for the quarter ended September 2025. The results are expected to be released on November 5.
This health insurer is expected to post quarterly earnings of $2.91 per share in its upcoming report, which represents a year-over-year change of -30.1%. The consensus EPS estimate for the quarter has been revised 2.3% lower over the last 30 days to the current level.
Humana's revenues are expected to be $31.98 billion, up 9.1% from the year-ago quarter.
Should You Invest in UnitedHealth Group Incorporated (UNH)?
Before you invest in UnitedHealth Group Incorporated (UNH), want to know the best stocks to buy for the next 30 days? Check out Zacks Investment Research for our free report on the 7 best stocks to buy.
Zacks Investment Research has been committed to providing investors with tools and independent research since 1978. For more than a quarter century, the Zacks Rank stock-rating system has more than doubled the S&P 500 with an average gain of +24.08% per year. (These returns cover a period from January 1, 1988 through May 6, 2024.)
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

UnitedHealth Group (UNH) Beats Q3 Earnings Estimates

Data is currently not available
Edit My Quotes
Add up to 25 symbols
To add symbols:
Type a symbol or company name. When the symbol you want to add appears, add it to My Quotes by selecting it and pressing Enter/Return.
Copy and paste multiple symbols separated by spaces.
These symbols will be available throughout the site during your session.
Data is currently not available
Edit My European Quotes
Add up to 25 instruments
To add instruments:
Type a instrument or company name. When the instrument you want to add appears, add it to My European Quotes by selecting it and pressing Enter/Return.
Copy and paste multiple instruments separated by spaces.
These instruments will be available throughout the site during your session.
Data is currently not available
Your symbols have been updated
You'll now be able to see real-time price and activity for your symbols on the My Quotes of Nasdaq.com.
Data is currently not available
Edit Watchlist
Add up to 20 symbols
To add symbols:
Type a symbol or company name. When the symbol you want to add appears, add it to Watchlist by selecting it and pressing Enter/Return.
Copy and paste multiple symbols separated by spaces.
These symbols will be available throughout the site during your session.
Data is currently not available
Opt in to Smart Portfolio
We are currently experiencing technical difficulties, please try again.
Smart Portfolio is supported by our partner TipRanks. By connecting my portfolio to TipRanks Smart Portfolio I agree to their Terms of Use.

Unitedhealth Group Q3 25 Earnings Conference Call At 8:00 AM ET

(RTTNews) - Unitedhealth Group, Inc. (UNH) announced a profit for third quarter that Decreased from last year but beat the Street estimates.
The company's bottom line totaled $2.348 billion, or $2.59 per share. This compares with $6.055 billion, or $6.51 per share, last year.
Excluding items, Unitedhealth Group, Inc. reported adjusted earnings of $2.650 billion or $2.92 per share for the period.
Analysts on average had expected the company to earn $2.81 per share. Analysts' estimates typically exclude special items.
The company's revenue for the period rose 12.2% to $113.161 billion from $100.820 billion last year.
Unitedhealth Group, Inc. earnings at a glance (GAAP) :
-Earnings: $2.348 Bln. vs. $6.055 Bln. last year. -EPS: $2.59 vs. $6.51 last year. -Revenue: $113.161 Bln vs. $100.820 Bln last year.
-Guidance: Full year EPS guidance: $16.25
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Unitedhealth Group, Inc. Q3 Profit Decreases, But Beats Estimates

Key Points
Warren Buffett's Berkshire Hathaway in the second quarter soldApple stock but started a new position in UnitedHealth Group.
Apple benefits from immense consumer loyalty and pricing power, but its sputtering innovation engine and lofty valuation are cause for concern.
UnitedHealth Group benefits from vertical integration, but profits are declining and the company is contending with several Justice Department investigations.
In the second quarter, Warren Buffett's Berkshire Hathaway sold 20 million shares of Apple (NASDAQ: AAPL). While it remains the largest holding in the company's $313 billion portfolio, Buffett has now sold 625 million shares since late 2023, representing approximately 70% of the position.
Meanwhile, Buffett started a brand new position in UnitedHealth Group (NYSE: UNH), a company whose stock has surged 5,600% over the last three decades, yet currently trades 42% below its record high.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue »
Here's what investors should know.
Apple: The stock Warren Buffett sold in the second quarter
Apple has cultivated a reputation for premium consumer electronics devices due to engineering expertise that spans hardware, software, and services. Particularly important is its ability to design custom semiconductors, which improve performance and power efficiency across its iPhone, iPad, and Mac products, and help the company control costs.
Apple accounted for 43% of smartphone sales in the second quarter, nearly three times more than its closest competitor Samsung. But the company also has a strong presence in personal computers, smartwatches, and tablets, and its ability to provide a seamless user experience across devices keeps consumers loyal and affords the company immense pricing power.
However, Apple's execution has been very disappointing where artificial intelligence (AI) is concerned. The introduction of Apple Intelligence (AI features for newer iPhone and Mac models) has so far failed to catalyze the upgrade cycle so many analysts predicted. And the most anticipated feature (a ChatGPT-like Siri) has been delayed repeatedly and is not expected until the first half of 2026.
Meanwhile, Apple's innovation engine has seemingly stalled. Its last groundbreaking new product was AirPods in 2017. But the company has now gone eight years without a major innovation, the longest stint since the iPod launched in 2002. That is particularly concerning because the stock trades at 40 times earnings, which is very rich for a company whose earnings are projected to grow at 10% annually in the next three years.
Here's the big picture: Apple is an excellent business. But the lack of innovation in recent years, especially with respect to artificial intelligence, and the stock's price tag give me pause. Buffett evidently has a great deal of confidence in the company given that it remains Berkshire's largest holding, but I think investors should avoid the stock until the valuation looks more reasonable.
UnitedHealth Group: A stock Warren Buffett bought in the second quarter
UnitedHealth Group is a diversified healthcare company that breaks its operations into two segments: (1) UnitedHealthcare provides health insurance to individuals and employers, and it administers Medicare and Medicaid plans; (2) Optum provides medical care services (Optum Health), pharmacy services (Optum Rx), and analytics services (Optum Insight).
That vertical integration gives UnitedHealth a holistic view patients, which theoretically helps control costs for the company and its clients. Morningstar analyst Julie Utterback writes, "Historically, this integrated strategy resulted in some of the best returns in the managed care industry." However, UnitedHealth Group faces several serious problems.
Medical costs and utilization of healthcare services have exceeded expectations, such that the company says it underestimated its expenses by $6.5 billion in 2025. The problem is spread throughout the business: About half of that total comes from Medicare plans, and the rest is split between individual, employer, and Medicaid plans. In turn, earnings fell 18% in the first half of 2025 as its profit margin contracted.
The company is also the subject of several Justice Department probes. The list includes investigations into whether its past acquisitions of doctor groups violated antitrust laws, and whether it deliberately inflated billings in its Medicare Advantage plans. The scope of the second investigation was recently widened to include pharmacy benefit manager Optum Rx. The Federal Trade Commission has also sued UnitedHealth for insulin price manipulation.
Here's the big picture: UnitedHealth Group shares currently trade 42% below the record high due to concerns about falling profits and the ongoing investigations. So, despite winning Berkshire Hathaway as a shareholder, I think there are too many unknowns for investors to buy the dip. I would keep this stock on my watchlist until we have more information about the Justice Department probes.
Should you invest $1,000 in Apple right now?
Before you buy stock in Apple, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Apple wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $590,357!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,141,748!*
Now, it’s worth noting Stock Advisor’s total average return is 1,033% — a market-crushing outperformance compared to 193% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.
*Stock Advisor returns as of October 27, 2025
Trevor Jennewine has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Apple and Berkshire Hathaway. The Motley Fool recommends UnitedHealth Group. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Warren Buffett Sells Apple Stock and Buys a Brand New Stock Up 5,600% in 30 Years

The following companies are expected to report earnings prior to market open on 10/28/2025. Visit our Earnings Calendar for a full list of expected earnings releases.
UnitedHealth Group Incorporated (UNH)is reporting for the quarter ending September 30, 2025. The hmo company's consensus earnings per share forecast from the 10 analysts that follow the stock is $2.80. This value represents a 60.84% decrease compared to the same quarter last year. The last two quarters UNH had negative earnings surprises; the latest report they missed by -15.7%. Zacks Investment Research reports that the 2025 Price to Earnings ratio for UNH is 22.42 vs. an industry ratio of 46.60.
NextEra Energy, Inc. (NEE)is reporting for the quarter ending September 30, 2025. The electric power utilities company's consensus earnings per share forecast from the 3 analysts that follow the stock is $1.04. This value represents a 0.97% increase compared to the same quarter last year. In the past year NEE has beat the expectations every quarter. The highest one was in the 2nd calendar quarter where they beat the consensus by 2.94%. Zacks Investment Research reports that the 2025 Price to Earnings ratio for NEE is 22.94 vs. an industry ratio of 19.80, implying that they will have a higher earnings growth than their competitors in the same industry.
American Tower Corporation (REIT) (AMT)is reporting for the quarter ending September 30, 2025. The reit company's consensus earnings per share forecast from the 3 analysts that follow the stock is $2.55. This value represents a 3.41% decrease compared to the same quarter last year. In the past year AMT has beat the expectations every quarter. The highest one was in the 2nd calendar quarter where they beat the consensus by 3.59%. Zacks Investment Research reports that the 2025 Price to Earnings ratio for AMT is 18.74 vs. an industry ratio of 12.90, implying that they will have a higher earnings growth than their competitors in the same industry.
Royal Caribbean Cruises Ltd. (RCL)is reporting for the quarter ending September 30, 2025. The leisure (recreational) company's consensus earnings per share forecast from the 7 analysts that follow the stock is $5.67. This value represents a 9.04% increase compared to the same quarter last year. In the past year RCL has beat the expectations every quarter. The highest one was in the 2nd calendar quarter where they beat the consensus by 6.83%. Zacks Investment Research reports that the 2025 Price to Earnings ratio for RCL is 20.21 vs. an industry ratio of 5.90, implying that they will have a higher earnings growth than their competitors in the same industry.
Sherwin-Williams Company (SHW)is reporting for the quarter ending September 30, 2025. The chemical company's consensus earnings per share forecast from the 7 analysts that follow the stock is $3.46. This value represents a 2.67% increase compared to the same quarter last year. Zacks Investment Research reports that the 2025 Price to Earnings ratio for SHW is 29.43 vs. an industry ratio of 8.00, implying that they will have a higher earnings growth than their competitors in the same industry.
Ecolab Inc. (ECL)is reporting for the quarter ending September 30, 2025. The chemical company's consensus earnings per share forecast from the 9 analysts that follow the stock is $2.06. This value represents a 12.57% increase compared to the same quarter last year. ECL missed the consensus earnings per share in the 2nd calendar quarter of 2025 by -0.53%. Zacks Investment Research reports that the 2025 Price to Earnings ratio for ECL is 36.87 vs. an industry ratio of 8.00, implying that they will have a higher earnings growth than their competitors in the same industry.
Corning Incorporated (GLW)is reporting for the quarter ending September 30, 2025. The communications company's consensus earnings per share forecast from the 4 analysts that follow the stock is $0.66. This value represents a 22.22% increase compared to the same quarter last year. In the past year GLW has beat the expectations every quarter. The highest one was in the 2nd calendar quarter where they beat the consensus by 5.26%. Zacks Investment Research reports that the 2025 Price to Earnings ratio for GLW is 35.39 vs. an industry ratio of 39.90.
PayPal Holdings, Inc. (PYPL)is reporting for the quarter ending September 30, 2025. The financial transactions company's consensus earnings per share forecast from the 14 analysts that follow the stock is $1.19. This value represents a 0.83% decrease compared to the same quarter last year. In the past year PYPL has beat the expectations every quarter. The highest one was in the 2nd calendar quarter where they beat the consensus by 7.69%. Zacks Investment Research reports that the 2025 Price to Earnings ratio for PYPL is 13.34 vs. an industry ratio of 12.50, implying that they will have a higher earnings growth than their competitors in the same industry.
United Parcel Service, Inc. (UPS)is reporting for the quarter ending September 30, 2025. The transportation company's consensus earnings per share forecast from the 10 analysts that follow the stock is $1.31. This value represents a 25.57% decrease compared to the same quarter last year. UPS missed the consensus earnings per share in the 2nd calendar quarter of 2025 by -0.64%. Zacks Investment Research reports that the 2025 Price to Earnings ratio for UPS is 13.50 vs. an industry ratio of 16.00.
Regeneron Pharmaceuticals, Inc. (REGN)is reporting for the quarter ending September 30, 2025. The biomedical (gene) company's consensus earnings per share forecast from the 7 analysts that follow the stock is $7.63. This value represents a 34.95% decrease compared to the same quarter last year. REGN missed the consensus earnings per share in the 1st calendar quarter of 2025 by -2.72%. Zacks Investment Research reports that the 2025 Price to Earnings ratio for REGN is 17.96 vs. an industry ratio of -2.10, implying that they will have a higher earnings growth than their competitors in the same industry.
Carrier Global Corporation (CARR)is reporting for the quarter ending September 30, 2025. The building company's consensus earnings per share forecast from the 5 analysts that follow the stock is $0.55. This value represents a 33.73% decrease compared to the same quarter last year. In the past year CARR has beat the expectations every quarter. The highest one was in the 2nd calendar quarter where they beat the consensus by 1.1%. Zacks Investment Research reports that the 2025 Price to Earnings ratio for CARR is 21.34 vs. an industry ratio of 23.20.
D.R. Horton, Inc. (DHI)is reporting for the quarter ending September 30, 2025. The building (residential/commercial) company's consensus earnings per share forecast from the 15 analysts that follow the stock is $3.29. This value represents a 16.07% decrease compared to the same quarter last year. Zacks Investment Research reports that the 2025 Price to Earnings ratio for DHI is 13.36 vs. an industry ratio of 12.30, implying that they will have a higher earnings growth than their competitors in the same industry.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Pre-Market Earnings Report for October 28, 2025 : UNH, NEE, AMT, RCL, SHW, ECL, GLW, PYPL, UPS, REGN, CARR, DHI

Last Friday, the three most widely followed benchmark indexes closed a winning week. The tech-heavy Nasdaq, the Dow Jones and the S&P 500 gained 2.3%, 2.2% and 1.9%, respectively.
The S&P 500 and Nasdaq registered their sharpest weekly advances since August, while the Dow Jones Industrial Average recorded its strongest weekly show since June.
The week’s trading reflects a mix of reduced trade-war fears between the United States and China, inflation coming in cooler than expected and U.S. sanctions on Russian oil firms shifting the energy market. The weaker-than-forecast inflation reading bolstered hopes for a rate cut by the Fed, lifting investor sentiment. Next week, markets will focus on upcoming central-bank commentary and big tech earnings.
Regardless of market conditions, we, here at Zacks, provide investors with unbiased guidance on how to beat the market.
As usual, Zacks Research guided investors over the past three months with its time-tested methodologies. Given the prevailing market uncertainty, you may want to look at our feats to prepare better for your next action.
Here are some of our key achievements:
Micron and Napco Security Surge Following Zacks Rank Upgrade
Shares of Micron Technology, Inc. MU have gained 77.3% (versus the S&P 500’s 5.3% increase) since it was upgraded to a Zacks Rank #1 (Strong Buy) on August 19.
Another stock, Napco Security Technologies, Inc. NSSC, which was also upgraded to a Rank #1 on August 28, has returned 14.8% (versus the S&P 500’s 4.7% increase) since then.
A hypothetical portfolio of Zacks Rank # 1 (Strong Buy) stocks returned +8.64% in 2025 (through September 1st) vs. +7.60% for the S&P 500 index.
This portfolio returned +22.4% in 2024, vs. +28% for the S&P 500 index and +19.9% for the equal-weight version of the S&P 500 index.
This hypothetical portfolio returned +20.65% in 2023 vs. +24.83% for the S&P 500 index and +15% for the equal-weight S&P 500 index.
The Zacks Model Portfolio - consisting of Zacks Rank #1 stocks – has outperformed the S&P index by more than 12 percentage points since 1988 (through September 1st, 2025, the Zacks # 1 Rank stocks generated an annualized average return of +23.8% vs. +11.3% for the S&P 500 index).
Image Source: Zacks Investment Research
Zacks Recommendation Upgrades PDD and Seacoast Banking
Shares of PDD Holdings Inc. PDD and Seacoast Banking Corporation of Florida SBCF have surged 9.6% (versus the S&P 500’s 4.4% rise) and 6.7% (versus the S&P 500’s 6.1% rise), respectively, since their Zacks Recommendation was upgraded to Outperform on August 29 and August 21.
While the Zacks Rank is our short-term rating system that is most effective over the one- to three-month holding horizon, the Zacks Recommendation aims to predict performance over the next 6 to 12 months. However, just like the Zacks Rank, the foundation for the Zacks Recommendation is trends in earnings estimate revisions.
The Zacks Recommendation classifies stocks into three groups — Outperform, Neutral and Underperform. While these recommendations are determined quantitatively, our analysts have the flexibility to override them for the 1100+ stocks they closely follow based on their better judgment of factors such as valuation, industry conditions and management effectiveness than the quantitative model.
To access our research reports with Zacks Recommendations for the 1100+ stocks we cover, click here>>>
Zacks Focus List Stocks Lam Research, Shopify Shoot Up
Shares of Lam Research Corporation LRCX, which belongs to the Zacks Focus List, have gained 56.4% over the past 12 weeks. The stock was added to the Focus List on December 5, 2016. Another Focus-List holding, Shopify Inc. SHOP, which was added to the portfolio on September 6, 2022, has returned 39% over the past 12 weeks. The S&P 500 has advanced 6.3% over this period.
The 50-stock Focus List portfolio returned 18.3% in 2025 (through September 30th, 2025) vs. +14.8% for the S&P 500 index and +9.9% for the equal-weight version of the index.
The Zacks Focus List portfolio returned +18.41% in 2024 vs. +25.04% for the S&P 500 index and +13% for the equal-weight S&P 500 index. The portfolio had returned +29.54% in 2023 vs. +26.28% for the S&P 500 index and +13.61% for the equal-weight S&P 500 index. In 2022, the portfolio returned -15.2% vs. the S&P 500 index’s -17.96%.
The portfolio leads the broader market over the preceding one, three, five and ‘since 2004’ periods. These annualized return comparisons are: +16.96% for the Focus List vs. +17.60% for the index over the one-year period, +26.77% vs. +24.94% over the 3-year period, +17.38% vs. +14.48% over the 5-year period, and +12.13% vs. +10.71% since 2004.
Unlock all of our powerful research, tools and analysis, including the Focus List, Zacks #1 Rank List, Equity Research Reports, Zacks Earnings ESP Filter, Premium Screener and more, as part of Zacks Premium. Gain full access now >>
Zacks ECAP Stocks Thermo Fisher & Fair Isaac Make Significant Gains
Thermo Fisher Scientific Inc. TMO, a component of our Earnings Certain Admiral Portfolio (ECAP), has jumped 19.7% over the past 12 weeks. Fair Isaac Corporation FICO has followed Thermo Fisher with 8.8% returns.
The Zacks Earnings Certain Admiral Portfolio (ECAP), which consists of 30 concentrated, ultra-defensive, long-term Buy-and-Hold stocks, returned +0.20% in the second quarter of 2025 vs. the S&P 500 index’s +10.94% gain (SPY ETF). In the year-to-date period through June 30th, the portfolio returned +3.93% vs. +6.20% gain for the S&P 500 index.
For the year 2024, the portfolio returned +16.26% vs. +24.89% for the S&P 500 index (SPY ETF).
In 2023, the portfolio returned +12.17% vs. +26.28% for the S&P 500 index. The portfolio returned -4.7% in 2022 vs. the S&P 500 index’s -17.96%.
With little to no turnover and annual rebalance periodicity, ECAP seeks to minimize capital loss by holding shares of companies whose earnings streams exhibit a proven 20+ year track record of surviving recessionary periods with minimal impact on aggregate earnings growth relative to the overall S&P 500.
The ECAP and many other model portfolios are available as part of Zacks Advisor Tools, a cloud-based solution to access Zacks award-winning stock, mutual fund and ETF research. Click here to schedule a demo.
Zacks ECDP Stocks UnitedHealth and 3M Outperform Peers
UnitedHealth Group Incorporated UNH, which is part of our Earnings Certain Dividend Portfolio (ECDP), has returned 29% over the past 12 weeks. Another ECDP stock, 3M Company MMM, has climbed 11.4% over the same time frame. Of course, the inclination of investors toward quality dividend stocks to secure an income stream amid heightened market volatility contributed to this performance.
With an extremely low beta and a history of minimum earnings variability over the last 20+ years, this 25-stock portfolio helps significantly mitigate risk.
The Zacks Earnings Certain Dividend Portfolio (ECDP) returned -3.17% in 2025 Q2 vs. the S&P 500 index’s +10.94% gain and the Dividend Aristocrats ETF’s (NOBL) -0.09% return. Year-to-date (through June 30th), the portfolio returned +2.38% vs. +2.18% gain for the Dividend Aristocrat ETF.
For the full year 2024, the portfolio returned +6.95% vs. +24.89% for the S&P 500 index and +6.72% for NOBL.
The portfolio returned -0.9% in 2023 vs. +26.28% for the S&P 500 index and +8.11% for NOBL. The portfolio returned -2.3% in 2022 vs. -17.96% for the S&P 500 index and -8.34% for NOBL.
Click here to access this portfolio on Zacks Advisor Tools.
Zacks Top 10 Stock Credo Technology Delivers Solid Returns
Credo Technology Group Holding Ltd CRDO, from the Zacks Top 10 Stocks for 2025, has jumped 131.4% year to date compared with the S&P 500 Index’s 15.6% increase.
The Top 10 portfolio returned +26.47% this year (through the end of September 2025) vs. +14.84% for the S&P 500 index and +9.9% for the equal-weight version of the index.
The Top 10 portfolio returned +62.98% in 2024, vs. +25.04% for the S&P 500 index and +13% for the equal-weight version of the index. The portfolio had returned +25.15% in 2023 vs. +26.28% for the S&P 500 index.
Since 2012, the Top 10 portfolio has produced a cumulative return of +2,553.1% through the end of September 2025 vs. +545.2% for the S&P 500 index and +396.4% for the equal-weight version of the index. The portfolio has produced an average return of +26.6% in the period 2012 through September 30, 2025, vs. +13.1% for the S&P 500 index and +10.5% for the equal-weight version of the index.
Beyond Nvidia: AI's Second Wave Is Here
The AI revolution has already minted millionaires. But the stocks everyone knows about aren't likely to keep delivering the biggest profits. Little-known AI firms tackling the world's biggest problems may be more lucrative in the coming months and years.
See "2nd Wave" AI stocks now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

UnitedHealth Group Incorporated

Sign up and unlock all the capabilities of the AI-screener